<DOC>
	<DOC>NCT01050751</DOC>
	<brief_summary>This is a randomized study to assess whether the pharmacokinetics of a new single 750 mg tablet is similar to 3 x 250 mg tablets (750 mg total).</brief_summary>
	<brief_title>Bioavailability Of Lersivirine Single 750 Mg Tablet Versus 3 X 250 Mg Tablets</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2. Total body weight &gt;50 kg (110 lbs). Treatment with an investigational drug within 30 days or 5 halflives or local regulation (whichever is longer) preceding the first dose of study medication. Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 halflives (whichever is longer) prior to the first dose of study medication. History of regular alcohol consumption exceeding 14 drinks/week for women and 21 drinks/week for men (1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard liquor).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Bioavailability</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Lersivirine</keyword>
	<keyword>UK-453</keyword>
	<keyword>061</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>